Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kohli, Manish
Huang, Xiaoyi
Yuan, Tiezheng
Sun, Zhifu
Costello, Brian Addis
Quevedo, Fernando
Tan, Winston
Nandy, Debashis
Longenbach, Sherri
Wang, Liang
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Mayo Clin, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
260
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    Nemtsova, E. R.
    Pankratov, A. A.
    Morozova, N. B.
    Tischenko, V. K.
    Petriev, V. M.
    Krylov, V. V.
    Shegay, P. V.
    Ivanov, S. A.
    Kaprin, A. D.
    BIOLOGY BULLETIN, 2022, 49 (12) : 2285 - 2297
  • [32] Radium-223 for Metastatic Castrate-Resistant Prostate Cancer
    Sindhu, Kunal K.
    Nehlsen, Anthony D.
    Stock, Richard G.
    PRACTICAL RADIATION ONCOLOGY, 2022, 12 (04) : 312 - 316
  • [33] Current state of theranostics in metastatic castrate-resistant prostate cancer
    Nindra, Udit
    Lin, Peter
    Becker, Therese
    Roberts, Tara L.
    Chua, Wei
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2024, 68 (04) : 412 - 420
  • [34] Re: Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Sartor, Oliver
    Parker, Chris
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (09) : 717 - 717
  • [35] Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
    Pal, Sumanta K.
    Lewis, Brian
    Sartor, Oliver
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 583 - +
  • [36] Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer
    Culine, Stephane
    EUROPEAN JOURNAL OF CANCER, 2018, 97 : 30 - 32
  • [37] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    E. R. Nemtsova
    A. A. Pankratov
    N. B. Morozova
    V. K. Tischenko
    V. M. Petriev
    V. V. Krylov
    P. V. Shegay
    S. A. Ivanov
    A. D. Kaprin
    Biology Bulletin, 2022, 49 : 2285 - 2297
  • [38] The Sequencing Conundrum in Metastatic Castrate-resistant Prostate Cancer (mCRPC): the Rosemere Cancer Centre Experience to Unlocking the Optimal Sequence
    Pan, S.
    Kumar, V.
    Charnley, N.
    Parikh, O.
    Birtle, A.
    CLINICAL ONCOLOGY, 2016, 28 (05) : E14 - E14
  • [39] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Gupta, S.
    Yang, Q.
    Halabi, S.
    Tubbs, A.
    Gore, Y.
    George, D. J.
    Nanus, D. M.
    Antonarakis, E. S.
    Danila, D.
    Szmulewitz, R.
    Wenstrup, R. J.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1166
12345